Business
BioSpectrum Asia
WHO outlines recommendations to protect infants against RSV
The World Health Organization (WHO) has published its first-ever position paper on immunisation products to protect infants against respiratory syncytial virus (RSV) - the leading cause of acute lower respiratory infections in children globally.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Australia develops AI tool to ensure colorectal cancer patients receive correct dose of chemotherapy
University of Melbourne and Western Health researchers in Australia have developed a new artificial intelligence (AI) tool to prevent cancer patients from receiving incorrect doses of chemotherapy.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Gene Solutions, Shenzhen USK Bioscience to establish next-gen sequencing lab in Southern China
Vietnam-based startup Gene Solutions and Shenzhen USK Bioscience Co. (USKBio), a molecular diagnostics startup in China, have entered a strategic partnership through a Memorandum of Understanding (MoU).
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
“Many US-based firms are actively seeking new opportunities in Asia for R&D partnerships, clinical trials, and commercialisation”
As Hong Kong accelerates its transformation into a global biotech and MedTech powerhouse, BioSpectrum Asia spoke with Andy Wong, Head of Innovation & Technology at Invest Hong Kong (InvestHK), at BIO International in Boston. Wong discussed increasing American interest in Hong Kong's innovation landscape, spotlighted promising local companies, and shared insights on how strategic partnerships, robust policy frameworks, and cross-border collaborations with Mainland China are positioning Hong Kong as a vital bridge between Western innovators and Asia’s thriving biotech ecosystem. Edited excerpts;
4 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Samsung Biologics launches drug screening services, Samsung Organoids
South Korea-based Samsung Biologics, a leading contract development and manufacturing organisation (CDMO), has announced the launch of Samsung Organoids, advanced drug screening services to support clients in drug discovery and development.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Singapore leads S$10 M national effort to tackle muscle-loss due to ageing
To tackle the growing threat of muscle loss in Singapore's ageing population, SingHealth Duke-NUS Academic Medical Centre will spearhead a S$10 million research initiative into sarcopenia, marking the country's first comprehensive, large-scale programme focused on this condition marked by loss of muscle mass and strength.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Serum Institute of India partners with DNDi to advance development of new dengue treatment
Serum Institute of India (SII), a part of Cyrus Poonawalla Group, and the not-for-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi) have signed a Memorandum of Understanding (MoU) to accelerate the clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low- and middle-income countries (LMICs).
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
India opens computing facility to boost genomic research
The Indian Council of Medical Research (ICMR), under the Health Ministry, has marked a significant milestone in advancing India's public health research capabilities with the inauguration of its first High Performance Computing (HPC) facility at the ICMR-National Institute of Virology (NIV), Pune.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
UK to boost clinical trials under 10 Year Health Plan
Patients will receive the most cutting-edge treatments years earlier than planned under the government's 10 Year Health Plan, which will speed up clinical trials so the UK becomes a hotbed of innovation.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
India discovers novel nanozyme to prevent excess blood clotting
Researchers at the Indian Institute of Science (IISc), Bengaluru have developed an artificial metal-based nanozyme that can potentially be used to clamp down on abnormal blood clotting caused by conditions like pulmonary thromboembolism (PTE).
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Korea focuses on exercise-induced protein to revive ageing muscles and bones
A joint research team, at the Korea Research Institute of Bioscience and Biotechnology and Chonnam National University, South Korea, has discovered a key protein, CLCF1 (cardiotrophinlike cytokine factor 1), that plays a central role in mediating the health benefits of physical activity.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Singapore designs new biomaterial to show how ageing in heart could be reversed
A new lab-grown material has revealed that some of the effects of ageing in the heart may be slowed and even reversed.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Royal Society elects Duke-NUS' Prof. Wong Tien Yin for Fellowship
Recognised for his invaluable contributions to science and innovation, Professor Wong Tien Yin from Singapore-based Duke-NUS' Office of Academic Medicine has been elected to the Fellowship of the Royal Society, the UK's national academy of sciences.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Riding High on China & India Diabetes, Obesity Surge
Semaglutide, a drug used for diabetes and weight management, is produced by Novo Nordisk and sold under the brand names Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management.
2 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Why AI-Enabled ‘Dirty Drugs’ are Future for Longevity Medicine
Ageing is not a result of a single malfunction; it’s a gradual, systemic breakdown that touches everything. Researchers have long understood this and have mapped the tangled web of genes, pathways, enzymes, and signalling molecules involved. For decades, the pharmaceutical industry tried to simplify its way through the complexity of ageing. But now, with AI and polypharmacology, we finally have the tools to meet that complexity on its terms.
5 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
GenepoweRx and MGI Tech to accelerate AI-driven genomic solutions in personalised medicine
Indian startup GenepoweRx, a trailblazer in artificial intelligence (AI)-powered personalised medicine based on genomic insights, has announced a strategic collaboration with China-based MGI Tech Co.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Sanofi to accelerate development of new global vaccines in Abu Dhabi
The Department of Health - Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MOU) with Sanofi, a research and development-driven, AI-powered healthcare biopharma company.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
CEPI signs new agreement with US Dept of Defense focusing on disease outbreaks
Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) and the US Department of Defense, Joint Programme Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), have signed a new agreement that will enable the two organisations to collaborate on projects that expand global defences against disease outbreaks.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Sun Pharma names Kirti Ganorkar as new Managing Director
Sun Pharmaceutical Industries, based in India, has announced the appointment of Kirti Ganorkar as the Managing Director (MD) to succeed Dilip Shanghvi, effective September 1, 2025, with the entire business and all functions reporting to him.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
IRREPLACEABLE HUMAN TOUCH
The trend of virtual and remote healthcare—including diagnostics and treatment—is gaining traction globally. Telemedicine, in particular, saw a rapid acceleration during COVID-19, when in-person consultations were often avoided due to the risk of virus transmission. Both healthcare providers and patients embraced remote care as a safer alternative. According to a GlobalData survey, 56 per cent of healthcare professionals believe that the growth of telemedicine and remote care has enhanced patients’ control over their health management. Among them, 13 per cent strongly agreed, while 26 per cent remained neutral. Only 2 per cent disagreed and 3 per cent strongly disagreed, showing widespread acceptance of this shift.
2 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Qiagen inks new partnership to develop oncology assays
Qiagen has announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
US FDA halts new clinical trials that export Americans' cells for genetic experiments
The US Food and Drug Administration (FDA) has announced an immediate review of new clinical trials that involve sending American citizens' living cells to China and other hostile countries for genetic engineering and subsequent infusion back into US patients, sometimes without their knowledge or consent.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
New Zealand grants approval to prescribe psilocybin for treatmentresistant depression
Medsafe, New Zealand's regulator of medicines and medical devices, has given approval for psychiatrists to prescribe medicinal psilocybin for treating treatment-resistant depression.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Lupin, Sino Universal ink license and supply agreement for Tiotropium DPI in China
Indian pharma major Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialisation of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease (COPD).
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Brain Navi achieves US FDA approval for neurosurgical robot NaoTrac
Brain Navi Biotechnology, a medical robotics company founded in 2015 in Taiwan by surgeon and serial entrepreneur Jerry Chen, has reached another major milestone.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
Korea Smart Healthcare Association to build next-gen medical platform
The Korea Smart Healthcare Association and SL Foundation have signed a Memorandum of Understanding (MoU) to form a strategic partnership aimed at advancing Korea's medical technology innovation and enhancing global public health.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
WHO calls for global expansion of midwifery models of care
The World Health Organization (WHO) has released new guidance to help countries adopt and expand midwifery models of care - where midwives serve as the main care provider for women and babies throughout pregnancy, childbirth, and the postnatal period.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
PolyActiva secures AUD $40 M in Series C to advance ocular drug delivery
Australia-based PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, has secured AUD $40 million in Series C funding.
1 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
“APAC is dynamic and rapidly evolving, with tremendous growth in R&D and attractive market conditions”
With cell and gene therapy (CGT) representing a major advancement in medical treatments by directly targeting the root causes of diseases at the cellular or genetic level, GlobalData’s latest report predicts the CGT market to be worth $76 billion by 2030.
5 min |
BioSpectrum Asia July 2025
BioSpectrum Asia
“The burden on medical and long- term care systems due to ageing is expected to intensify in Japan”
Japan-headquartered Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, as the Leader of its Healthcare Sector in April this year. Under Shinomiya, Asahi Kasei’s Healthcare Sector plans to further advance its portfolio and global presence of pharmaceuticals, life science, and critical care products and services. BioSpectrum Asia took this opportunity to interact with the new leader to find out more about the company’s growth plans within Japan and internationally. Edited excerpts:
4 min |